EU Indication Extensions On Cards For Taltz, Truvada and Yervoy
Eli Lilly, Gilead and Bristol-Myers Squibb can look forward to product indication extensions after getting the OK from the European Medicines Agency’s CHMP. Other companies seeking extensions will be asked for more information.
You may also be interested in...
A new ATMP, two generics and a biosimilar got the thumbs up this week from the European Medicines Agency’s drug evaluation committee, the CHMP. The committee also recommended one product for conditional authorization and another for a pediatric use authorization, But it turned down a potential multiple myeloma therapy derived from sea squirts.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.